title: [Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up].
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of recombinant adenovirus p53 injection (SBN-1) in patients with laryngeal cancer.
  
  
  METHODS
  Twelve cases with laryngeal cancer, 11 males and 1 female, aged 59.5 +/- 12.4 years, were randomly divided into three groups of 4 patients. The patients received intratumor injection of SBN-1 at the dosage of 1 x 10(10)VP, 1 x 10(11)VP, or 1 x 10(12)VP once every other day for 2 courses of treatment with 5 times of injection as one course of treatment. Two days after the injection the patients were operated on. After the operation SBN-1 of the same doses was injected around the tumor bed. The patients were followed up for more than 3 years by correspondence and out-patient department examinations. ELISA was used to detect the serum anti-adenoviral IgG and IgM, and interleukin-2 receptor (IL-2R). Immunohistochemistry was used to examine the expression of p53 protein in the tumor tissues. Flow cytometry was used to examine the T cell subgroup. The symptoms and side effects were observed.
  
  
  RESULTS
  One patient in the 10(12)VP group presented self-limited fever (38.2-38.6 degrees C) and no other abnormality was observed after the SBN-1 injection. Specific antibody to SBN-1 turned from negative to positive two or three weeks after the first injection. P53 protein expression was significantly enhanced in tumors after injection of SBN-1. The serum level of IL-2R was 750 +/- 401 pg/ml before treatment and 552 +/- 203 pg/ml after treatment. The numbers of CD3, CD4, and CD8 were 66 +/- 10, 41 +/- 15, and 32 +/- 10 respectively before the treatment and were 67 +/- 9, 43 +/- 8, and 34 +/- 16 respectively after treatment, and the CD4/CD8 ratio was 1.4 +/- 0.6 before the treatment and was 1.6 +/- 0.9 after treatment. The abnormality in SIL-2R level and the disorder of T cell subgroup were improved in 2 cases. Followed up for over 3 years showed that all cases still lived free of cancer.
  
  
  CONCLUSIONS
  Safe and effective on laryngeal cancer without obvious adverse events, local injection of SBN-1 is a promising treatment.
authors.affiliation: TongRen Hospital, Capital University of Medical Sciences, Beijing 100015, China.
authors.forename: De-min
authors.initials: DM
authors.lastname: Han
authors.forename: Zhi-gang
authors.initials: ZG
authors.lastname: Huang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Zhen-kun
authors.initials: ZK
authors.lastname: Yu
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.forename: Xin
authors.initials: X
authors.lastname: Ni
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Chen
authors.forename: Jin-hua
authors.initials: JH
authors.lastname: Pan
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged